Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

2.3K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
2.3K
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

2.0K
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
2.0K
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

1.1K
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
1.1K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

2.3K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
2.3K
Asthma-IV: Nursing Management01:30

Asthma-IV: Nursing Management

4.0K
The nursing management of asthma is a comprehensive approach that relies heavily on the expertise and dedication of healthcare professionals. It involves thorough assessment, accurate diagnosis, strategic planning, effective implementation, and diligent evaluation. By meticulously following this step-by-step process, healthcare professionals play a crucial role in providing the best possible care and treatment for patients with asthma, enhancing their overall health and well-being.
First, in...
4.0K
Antiasthma Drugs: β2-Adrenoceptor Agonists01:25

Antiasthma Drugs: β2-Adrenoceptor Agonists

2.1K
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
2.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Education needs in oxygen therapy for individuals with interstitial lung disease.

BMJ open respiratory research·2026
Same author

Eating Epilepsy: Clinico-Electro-Imaging Profiles and Treatment Outcomes in Patients from Northeast India.

Annals of Indian Academy of Neurology·2026
Same author

"I just know I don't know": challenging the interpretation of clinical trials grounded in imperfect assumptions.

American journal of respiratory and critical care medicine·2026
Same author

Use of proton pump inhibitors and increased risk of fracture in type 2 DM and menopausal women: a systematic review and meta-analysis.

African health sciences·2026
Same author

Shining a light on substrate affinity of glutamate-binding protein. Single-molecule insights into pH-modulated glutamate binding.

Scientific reports·2026
Same author

The Quality Assessment of Reporting Methods and Results of Cost-Effectiveness Analyses Conducted on the Indian Population: A Methodological Systematic Review.

Value in health regional issues·2026

Related Experiment Video

Updated: Apr 3, 2026

Long Term Chronic Pseudomonas aeruginosa Airway Infection in Mice
15:43

Long Term Chronic Pseudomonas aeruginosa Airway Infection in Mice

Published on: March 17, 2014

24.1K

Macrolides for chronic asthma.

Kayleigh M Kew1, Krishna Undela, Ioanna Kotortsi

  • 1Population Health Research Institute, St George's, University of London, Cranmer Terrace, London, UK, SW17 0RE.

The Cochrane Database of Systematic Reviews
|September 16, 2015
PubMed
Summary
This summary is machine-generated.

Macrolide antibiotics show no significant benefit over placebo for most asthma outcomes. However, they may slightly improve lung function and potentially benefit non-eosinophilic asthma, though evidence quality is very low.

More Related Videos

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

32.7K
Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

41.7K

Related Experiment Videos

Last Updated: Apr 3, 2026

Long Term Chronic Pseudomonas aeruginosa Airway Infection in Mice
15:43

Long Term Chronic Pseudomonas aeruginosa Airway Infection in Mice

Published on: March 17, 2014

24.1K
Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

32.7K
Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

41.7K

Area of Science:

  • Pulmonology
  • Pharmacology
  • Clinical Trials

Background:

  • Asthma is a chronic airway inflammatory disease causing coughing, wheezing, and breathing difficulties.
  • Macrolides, antibiotics with anti-inflammatory properties, are used for long-term asthma symptom management.
  • The efficacy of macrolides in managing chronic asthma requires thorough assessment.

Purpose of the Study:

  • To evaluate the effectiveness of macrolide antibiotics in managing chronic asthma.
  • To synthesize evidence from randomized controlled trials on macrolide use in asthma.

Main Methods:

  • Conducted a systematic search of the Cochrane Airways Group Specialised Register and other sources.
  • Included randomized controlled trials (RCTs) of macrolides versus placebo in children and adults with chronic asthma for over four weeks.
  • Extracted data from 23 RCTs involving 1513 participants.

Main Results:

  • The overall quality of evidence was very low due to heterogeneity, bias, and imprecision.
  • Macrolides did not demonstrate superiority over placebo for most clinical outcomes, including exacerbations and oral steroid use.
  • A potential benefit was observed in some lung function measures (FEV1) and a possible steroid-sparing effect in a subgroup of patients on oral corticosteroids.
  • Biomarkers of asthma activity were reduced by macrolides but without associated clinical benefits.

Conclusions:

  • Current evidence does not support macrolides as superior to placebo for most asthma outcomes.
  • The very low quality of evidence precludes definitive conclusions on benefits or harms.
  • Further research is needed, particularly focusing on accurate outcome reporting and exploring potential benefits in non-eosinophilic asthma.